Modulator Therapy Improves Lives of Patients With Cystic Fibrosis With Severe Lung Disease
Modulator Therapy Improves Lives of Patients With Cystic Fibrosis With Severe Lung Disease https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=gPatients receiving ETI on a compassionate use basis experienced substantial clinical improvement. The development of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, most recently elexacaftor/tezacaftor/ivacaftor (ETI), has transformed the treatment of patients with cystic fibrosis. A new study from researchers at Nationwide Children’s Hospital shows that ETI therapy has the potential to change even…
read more